,,ii #aagth ,,congress #ast ,session ,s4 #aabc ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,april #ad1 #bjba,mrs4 ,blackburn introduced the following bill2 which was read twice and referred to the ,committee on ,finance ,a ,,bill ,to preserve non-interference under the ,medicare part ,d ,prescription ,drug ,benefit program4 #a4 ,short title ,this ,act may be cited as the ,preserving ,innovation for the ,next ,generation ,act or the ,,ping ,act4 #b4 ,findings ,congress makes the following findings3 7#a7 ,since implementation1 the ,medicare ,prescription ,drug ,benefit program under part ,d of title ,,xviii of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aja et seq47 7referred to in this section as ,medicare part ,d7 has succeeded beyond expectations in providing affordable prescription drug coverage for more than #de1jjj1jjj seniors and disabled individuals4 7#b7 ,the competitive market has kept total ,medicare part ,d costs below original estimates1 while still offering beneficiaries steady premiums and a variety of alternative formularies and benefit design4 7#c7 ,this competitive pricing structure works1 in large part1 due to the non-interference clause under ,medicare part ,d which provides for robust private market negotiation without undue government interference4 7#d7 ,the ,congressional ,budget ,office repeatedly has said that government negotiation would have a negligible impact on ,medicare part ,d spending unless the government also restricted access to medications4 7#e7 ,to achieve any significant savings1 the government would need to impose access or coverage restrictions on medications4 ,in fact1 limiting options will likely result in costs shifting to higher spending for other ,medicare services and negatively impact the health of seniors without helping to reduce government spending4 7#f7 ,having a broad range of treatment options is fundamental to providing good care to all patients1 but particularly so for the ,medicare population1 who are more likely to be affected by multiple chronic conditions4 ,with the advent of personalized medicines and targeted therapies--where the underlying molecular drivers of disease help identify and direct precise1 targeted treatment choices--limiting access reduces the vast potential of breakthrough science to revolutionize care4 ,therefore1 it is imperative to ensure beneficiaries have access to a broader range of medicines to best meet their health needs4 7#g7 ,medicare beneficiaries would not be better off if ,medicare part ,d drug coverage were administered by the ,federal ,government in the same way as the ,veterans ,administration4 ,many veterans rely on other sources to supplement their ,veterans ,administration drug coverage due to restrictions that limit their access to needed medications4 ,more than half of all veterans supplement their ,veterans ,administration benefits with other sources of drug coverage1 including ,medicare part ,d4 ,a recent ,veterans ,administration survey shows that approximately #hj4d percent of veterans had both ,veterans ,administration and non-,veterans ,administration health coverage and1 among those in ,medicare1 #cc4b percent have ,medicare part ,d for prescription drug coverage4 7#h7 ,imposing a restrictive ,veterans ,administration-type formulary on ,medicare part ,d is unlikely to work for the diverse group of more than #de1jjj1jjj beneficiaries enrolled in ,medicare part ,d4 ,evidence show that seniors would have limited choices and fewer medicines available to them4 ,a recent analysis by ,xcenda found that of the top #bjj part ,d brand name drugs1 #gd percent or more were covered across stand-alone prescription drug plans and ,medicare ,advantage prescription drug plans1 compared with #eb percent that could be covered by the ,veterans ,administration formulary4 7#i7 ,a national formulary would restrict access to affordable and vital prescriptions many ,medicare beneficiaries rely on4 ,robust patient access to a full range of medicines has been a cornerstone of ,medicare part ,d4 ,restricting access to medicines can significantly reduce adherence4 ,poorer medication adherence1 in turn1 can lead to worse health outcomes and higher overall spending4 7#aj7 ,price controls or large penalties to force companies to comply with so-called negotiations have resulted in restricted access abroad and threaten similar restrictions on access in the ,united ,states4 ,research demonstrates that government price setting reduces access for patients and results in fewer or delayed treatment options--nearly #ij percent of new medicines launched globally in the past decade are currently available to patients in the ,united ,states1 only about half are available to patients in other countries like ,france and ,canada4 7#aa7 ,limiting patient access to medicines contradicts the foundational principles of ,medicare part ,d and the value beneficiaries derive from the program--a recent survey shows that more than #ij percent of ,medicare beneficiaries are satisfied with their drug coverage and more than #hj percent said it is important to them to have a variety of prescription drug plans under ,medicare part ,d from which to choose4 #c4 ,sense of the ,senate ,it is the sense of the ,senate that non-interference in the ,medicare part ,d ,prescription ,drug ,benefit program under section #ahfj;,d-#aa7;i7 of the ,social ,security ,act 7#db ,u4,s4,c4 #aciew-#aaa7;i77 should not be repealed4 #d4 ,prohibition on ,,cmi testing of models that would repeal noninterference ,section #aaae;,a7b7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acae;a7b77 is amended by adding at the end the following new paragraph3 7#e7 ,prohibition on testing of models that would repeal noninterference ,the ,,cmi shall not test any model that would repeal or require a waiver of section #ahfj;,d-#aa7;i74 4